SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tonyt who wrote (392)8/17/1997 10:05:00 AM
From: Henry Niman   of 2173
 
tonyt, I don't follow AMLN as closely as some other San Diego biotechs :-), but I'm not overly optomistic about Friday's press release. The type II market is much larger than type I and so far the results in that group are iffy at best. The onging trials may help define a subgroup, but the fact that such a search takes so long and only produces minimal results is not a good sign. Of course the type II target population is huge (although it may be decreased by TZDs and Rexinoids), so even a sub-group could be significant, but identification is difficult and benefits have not been demonstrated.
If I were an AMLN shareholder (which I'm not), I would not be jumping up and down because of Friday's results. Of course the street is frequently unpredictable, and with the right spins, the stock could go up, but I would not be surprised by a significant decline.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News